CUMYL-CBMINACA

CUMYL-CBMINACA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class B ;
Identifiers
	IUPAC name 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide;
CAS Number	3001262-62-7 ;
PubChem CID	155884799 ;
ChemSpider	90606548 ;
UNII	3DAF3CP9N5 ;
CompTox Dashboard (EPA)	DTXSID101336534 ;
Chemical and physical data
Formula	C22H25N3O
Molar mass	347.462 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC(C)(NC(=O)c3nn(CC1CCC1)c2ccccc23)c4ccccc4;
	InChI InChI=1S/C22H25N3O/c1-22(2,17-11-4-3-5-12-17)23-21(26)20-18-13-6-7-14-19(18)25(24-20)15-16-9-8-10-16/h3-7,11-14,16H,8-10,15H2,1-2H3,(H,23,26); Key:CFMZQSDQCNKGII-UHFFFAOYSA-N;

Last updated July 02, 2025

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,^[1] first being identified in Germany in February 2020.^[2] It is illegal in Finland.^[3]

References

↑ Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, et al. (August 2021). "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis. 13 (8): 1499–1515. doi: 10.1002/dta.3038 . PMID 33788409.
↑ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
↑ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market]. Finlex (in Finnish). Finnish Ministry of Justice.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[pmid33788409-1] Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, et al. (August 2021). "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis. 13 (8): 1499–1515. doi: 10.1002/dta.3038 . PMID 33788409.

[2] "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.

[3] "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market]. Finlex (in Finnish). Finnish Ministry of Justice.

[1]

[2]

[3]

CUMYL-CBMINACA

See also

References